Lammerich A - Search Results

1

A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma.

Belogurova MB, Kizyma ZP, Garami M, Csóka M, Lamson MJ, Buchner A, Bias P, Lammerich A. Belogurova MB, et al. Among authors: lammerich a. Cancer Chemother Pharmacol. 2017 Jan;79(1):155-164. doi: 10.1007/s00280-016-3216-2. Epub 2016 Dec 16. Cancer Chemother Pharmacol. 2017. PMID: 27986986 Free PMC article. Clinical Trial.

2

Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.

Buchner A, Lammerich A, Abdolzade-Bavil A, Müller U, Bias P. Buchner A, et al. Among authors: lammerich a. Curr Med Res Opin. 2014 Dec;30(12):2523-33. doi: 10.1185/03007995.2014.962131. Epub 2014 Sep 25. Curr Med Res Opin. 2014. PMID: 25251999 Clinical Trial.

3

Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.

Volovat C, Bondarenko I, Gladkov O, Buchner A, Lammerich A, Müller U, Bias P. Volovat C, et al. Among authors: lammerich a. Support Care Cancer. 2016 Dec;24(12):4913-4920. doi: 10.1007/s00520-016-3347-3. Epub 2016 Aug 8. Support Care Cancer. 2016. PMID: 27501966 Clinical Trial.

4

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.

Link H, Illerhaus G, Martens UM, Salar A, Depenbusch R, Köhler A, Engelhardt M, Mahlmann S, Zaiss M, Lammerich A, Bias P, Buchner A. Link H, et al. Among authors: lammerich a. Support Care Cancer. 2021 May;29(5):2519-2527. doi: 10.1007/s00520-020-05711-7. Epub 2020 Sep 17. Support Care Cancer. 2021. PMID: 32944800 Free PMC article. Clinical Trial.

5

Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women.

Lammerich A, Bias P, Gertz B. Lammerich A, et al. Int J Womens Health. 2015 Jul 16;7:707-16. doi: 10.2147/IJWH.S83418. eCollection 2015. Int J Womens Health. 2015. PMID: 26213478 Free PMC article.

6

Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation.

Lammerich A, Mueller A, Bias P. Lammerich A, et al. Reprod Biol Endocrinol. 2015 Dec 1;13:130. doi: 10.1186/s12958-015-0124-y. Reprod Biol Endocrinol. 2015. PMID: 26621118 Free PMC article. Clinical Trial.

7

A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy.

Federman N, Dragomir MD, Kizyma Z, Roganovic J, Bias P, Lammerich A, Ben Arie ZR, Zou L, Hoehn G, Buchner A. Federman N, et al. Among authors: lammerich a. J Pediatr Hematol Oncol. 2019 Oct;41(7):525-531. doi: 10.1097/MPH.0000000000001542. J Pediatr Hematol Oncol. 2019. PMID: 31274668 Clinical Trial.

8

Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study.

Lammerich A, Balcke P, Bias P, Mangold S, Wiesholzer M. Lammerich A, et al. Clin Ther. 2016 Feb;38(2):276-287.e4. doi: 10.1016/j.clinthera.2015.11.018. Epub 2015 Dec 19. Clin Ther. 2016. PMID: 26708119

9

Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors.

Abboud CN, Lang N, Fung H, Lammerich A, Buchner A, Liu P, Mueller U, Pettengell R, Diel IJ, Link H, Pathak A. Abboud CN, et al. Among authors: lammerich a. Support Care Cancer. 2019 Jul;27(7):2569-2577. doi: 10.1007/s00520-018-4522-5. Epub 2018 Nov 15. Support Care Cancer. 2019. PMID: 30443809

10

Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profile.

Abdolzade-Bavil A, von Kerczek A, Cooksey BA, Kaufman T, Krasney PA, Pukac L, Görlach M, Lammerich A, Scheckermann C, Allgaier H, Shen WD, Liu PM. Abdolzade-Bavil A, et al. Among authors: lammerich a. J Clin Pharmacol. 2016 Feb;56(2):186-94. doi: 10.1002/jcph.578. Epub 2015 Sep 1. J Clin Pharmacol. 2016. PMID: 26105553

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page